Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.
The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.
Eli Lilly & Co. (LLY) director Lilly Endowment Inc. reported open-market sales of Eli Lilly common stock on 11/25/2025. The Endowment sold 5,043 shares at a weighted average price of $1,108.71, 9,249 shares at a weighted average price of $1,109.449, and 1,340 shares at a weighted average price of $1,110.527, for a total of 15,632 shares sold.
After these transactions, Lilly Endowment Inc. beneficially owned 92,196,978 shares of Eli Lilly common stock, held directly. The prices reported reflect multiple trades within narrow ranges for each block of shares. This filing is identified as the second of two Forms 4 filed by the reporting person on the same date, covering transactions numbered 31 through 33 of 33 total transactions.
Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including $1,073.735 and $1,107.48 per share, and footnotes detailing underlying trade ranges from $1,073.78 to $1,107.95. After completing these reported sales, Lilly Endowment Inc. beneficially owned 92,212,610 shares of Eli Lilly common stock, held directly. This filing is identified as the first of two Forms 4 filed the same day, covering transactions numbered 1 through 30 of 33 total.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co (LLY), reported multiple sales of Eli Lilly common stock on 11/24/2025. The largest block shown was 120,016 shares sold at a weighted average price of $1,068.175 per share, with additional smaller sales the same day at weighted average prices between about $1,069.477 and $1,073.597 per share.
After these transactions, Lilly Endowment directly beneficially owned 92,359,671 shares of Eli Lilly common stock. The prices reported are weighted averages for multiple trades within narrow price ranges, and the reporting person has indicated a willingness to provide detailed trade breakdowns upon request.
Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.
The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc. filed a Form 144 notice covering a proposed sale of 305,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets, with an aggregate market value of $323,208,500. The notice lists 945,383,757 Eli Lilly shares outstanding. The Endowment’s shares being sold trace back to a large historical gift; it reports acquiring 38,400,000 Eli Lilly common shares via a gift from the J.K. Lilly Sr. Trust dated in the 1930s–1940s.
The filing also details extensive recent selling activity by Lilly Endowment. Over the past three months, it executed multiple Eli Lilly stock sales on the NYSE and NASDAQ, including transactions such as 351,015 shares on 10/01/2025 for gross proceeds of $284,653,451.48 and 305,000 shares on 11/12/2025 for $308,411,211.50. Individual daily trades during this period often exceeded 100,000 shares, with gross proceeds frequently above $80 million per day.
Eli Lilly and Company reported that its Board of Directors has elected Carolyn R. Bertozzi, Ph.D. as a new director, effective December 8, 2025. She is 59 and holds key academic roles at Stanford University, including Professor of Chemistry, Chemical & Systems Biology, and Radiology, and serves as an Investigator of the Howard Hughes Medical Institute.
Dr. Bertozzi will join Lilly’s Science and Technology Committee and the Ethics and Compliance Committee, bringing additional scientific and governance expertise. The Board has determined that she is independent under New York Stock Exchange standards and the company’s own guidelines. She will stand for election by shareholders at the annual meeting in May 2026 and will receive compensation under Lilly’s standard director compensation program.
Lilly Endowment Inc., a director of Eli Lilly & Co. (LLY), reported open-market sales of a total of 37,148 shares of common stock on 11/20/2025. The sales were executed in multiple tranches at weighted average prices ranging from $1,050.364 to $1,055.391 per share, with underlying trade prices spanning from $1,050.00 to $1,055.59, as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owns 92,607,304 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly and Company (LLY), reported multiple sales of Eli Lilly common stock on 11/19/2025. The transactions were open-market sales at weighted average prices between about $1,050 and $1,055 per share, executed in several blocks including 96,516 shares and 28,768 shares. After these sales, the reporting person beneficially owned 92,644,452 shares of Eli Lilly common stock, held directly. The prices disclosed are weighted averages for trades within narrow price ranges, and the reporting person notes that detailed trade information is available upon request.
Eli Lilly & Co. reported insider selling by a director on Form 4. On 11/18/2025, the reporting person executed a series of open-market sales of Eli Lilly common stock, coded "S" for sale. Across ten tranches, the director sold a total of 60,213 shares at weighted average prices ranging from about $1,030 to $1,040 per share, with each tranche reported alongside a specific weighted average price and price range.
Following these transactions, the reporting person directly beneficially owned 92,811,978 shares of Eli Lilly common stock. The filing notes that detailed breakouts of the individual trade prices within each weighted range are available upon request. The form is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.